ZHONGZHIPHARM (03737) announced its interim results, with a profit attributable to shareholders of 9.116 million yuan, an increase of 3.79% year-on-year.

19:30 26/08/2026

China Pharmaceutical Industry (03737) announced its interim results for the six months ending June 30, 2026, with revenue of 790 million yuan (RMB, the same hereinafter), a year-on-year decrease of 10.28%; the profit attributable to equity holders of the parent company was 9.116 million yuan, an increase of 3.79% year-on-year; basic earnings per share were 1.1 cents.

ZHONGZHIPHARM (03737) announced its interim results for the six months ended June 30, 2026, with revenue of 790 million yuan (RMB, the same below), a year-on-year decrease of 10.28%; profit attributable to equity holders of the parent company was 9.116 million yuan, a year-on-year increase of 3.79%; basic earnings per share were 1.1 cents.

CCIAM FUTURE EN(00145) announced its interim results, reporting a loss attributable to shareholders of HK$8.928 million, an increase of 1.9% year-on-year.

CR BEVERAGE (02460) released its mid-term results, with a profit attributable to shareholders of 592 million yuan, firmly adhering to its brand-driven development strategy.

NAYUKI (02150) achieved revenue of 1.8925 billion yuan in the first half of the year, continuously enriching its product matrix.

CCIAM FUTURE EN(00145) announced its interim results, reporting a loss attributable to shareholders of HK$8.928 million, an increase of 1.9% year-on-year.

CR BEVERAGE (02460) released its mid-term results, with a profit attributable to shareholders of 592 million yuan, firmly adhering to its brand-driven development strategy.

NAYUKI (02150) achieved revenue of 1.8925 billion yuan in the first half of the year, continuously enriching its product matrix.